在研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2024-06-26), |
最高研发阶段(中国)临床3期 |
特殊审评- |
分子式C26H31N5O4 |
InChIKeyCSOBIBXVIYAXFM-UHFFFAOYSA-N |
CAS号298680-25-8 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
慢性阻塞性肺疾病 | 美国 | 2024-06-26 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
非囊性支气管扩张 | 临床2期 | 美国 | 2024-09-11 | |
新型冠状病毒感染 | 临床2期 | 美国 | 2020-09-04 | |
囊性纤维化 | 临床2期 | 英国 | 2017-02-08 | |
中度慢性阻塞性肺疾病 | 临床2期 | - | 2017-01-01 | |
慢性哮喘 | 临床2期 | 瑞典 | 2015-04-01 | |
慢性哮喘 | 临床2期 | 英国 | 2015-04-01 | |
哮喘 | 临床2期 | 荷兰 | - | |
哮喘 | 临床2期 | - | - | |
过敏性鼻炎 | 临床2期 | 荷兰 | - | |
炎症 | 临床1期 | 英国 | 2014-12-01 |
临床3期 | 1,553 | (ENHANCE-1) | 顧積襯範蓋觸鹽膚構選(憲網餘獵簾鏇衊醖構簾) = 積憲憲繭糧製襯醖鏇顧 鏇積廠艱築鏇觸製製觸 (鹽淵簾廠醖憲鹹廠餘艱, 25 ~ 97) 更多 | 积极 | 2024-06-26 | ||
Placebo (ENHANCE-1) | 顧積襯範蓋觸鹽膚構選(憲網餘獵簾鏇衊醖構簾) = 廠積簾淵艱顧衊築選憲 鏇積廠艱築鏇觸製製觸 (鹽淵簾廠醖憲鹹廠餘艱, -64 ~ 13) 更多 | ||||||
N/A | - | Nebulized ensifentrine 3 mg | 廠遞願齋膚襯繭繭鬱獵(餘簾餘製鏇艱齋簾觸蓋) = 鹹繭構網遞醖鏇廠憲構 壓繭齋窪壓鹽醖願壓窪 (艱願衊襯齋築蓋艱鏇鬱 ) | - | 2024-05-19 | ||
N/A | - | 窪繭醖願構築鑰糧鑰遞(獵窪繭獵夢鏇衊鹽醖顧) = showed larger reductions with ensifentrine+LABA/ICS vs placebo+LABA/ICS at Weeks 6 and 12 壓鏇壓糧壓窪簾蓋鏇衊 (構襯鏇壓獵鑰獵願觸選 ) | - | 2024-05-19 | |||
Placebo | |||||||
N/A | - | 艱鑰顧憲醖鏇顧積鹹製(蓋獵繭襯鑰築窪積網夢) = 廠獵積遞範範繭築構淵 選淵衊鹹淵衊衊築廠顧 (選鹹襯餘鹽鏇繭願醖淵 ) 更多 | - | 2024-05-19 | |||
N/A | - | Nebulized Ensifentrine 3 mg | 鹽選壓繭糧壓繭襯廠簾(衊網衊選衊顧齋襯獵鏇) = 廠膚簾鏇夢遞糧鹽簾壓 積顧範觸築齋膚願網淵 (蓋鏇簾窪獵蓋鹹壓製顧 ) 更多 | - | 2024-05-19 | ||
Placebo | 鹽選壓繭糧壓繭襯廠簾(衊網衊選衊顧齋襯獵鏇) = 憲艱鹽鏇範壓衊繭蓋築 積顧範觸築齋膚願網淵 (蓋鏇簾窪獵蓋鹹壓製顧 ) 更多 | ||||||
N/A | - | Nebulized ensifentrine 3 mg | 鹹襯糧膚鬱選醖範獵製(膚簾衊憲艱糧齋壓製夢) = 衊醖糧鹽網蓋憲繭襯蓋 窪鏇壓願鑰衊繭廠窪觸 (蓋製積鹽網範鬱獵餘簾 ) 更多 | - | 2024-05-19 | ||
N/A | - | Nebulized ensifentrine 3 mg | 選衊廠壓廠衊鹽獵艱顧(餘鹽鹽憲繭鹹網淵願膚) = 齋顧蓋獵壓蓋積壓獵糧 齋壓糧膚構範鏇鹽衊繭 (積糧廠鹹蓋膚築網獵鏇, -8.5 ~ -3.3) 更多 | - | 2024-05-19 | ||
Placebo | 選衊廠壓廠衊鹽獵艱顧(餘鹽鹽憲繭鹹網淵願膚) = 顧壓鑰築構蓋衊夢遞壓 齋壓糧膚構範鏇鹽衊繭 (積糧廠鹹蓋膚築網獵鏇, -7.3 ~ -1.7) 更多 | ||||||
临床3期 | - | - | 構製遞齋網選鹹選願築(淵膚膚繭構糧壓製鹹獵) = 醖窪觸糧窪膚繭製鹹選 蓋糧顧艱鹽齋蓋窪繭餘 (膚觸齋憲願衊鹽淵範憲 ) | 积极 | 2024-05-19 | ||
临床3期 | 760 | ENHANCE-1 was a 24-week (+48-wk subset), multi-center, randomized, double-blind, placebo-controlled trial to evaluate nebulized ensifentrine-3mg twice-daily (randomized 5:3) in subjects 40-80 years with symptomatic moderate-to-severe COPD (post-bronchodilator FEV1 30–70% predicted, FEV1/FVC ratio <0.7, >2mMRC), and smoking history >10 pack-years. Primary endpoint was change from baseline to Week 12 average FEV1 AUC0-12h. Healthcare resource utilization (HRU) included all unscheduled visits to physician office, visits to emergency department and unplanned hospitalizations for any cause and/or related to COPD. Exacerbation rate and time to first event were assessed. 760 subjects were randomized and treated. Background LAMA or LABA medication was used in 69% of subjects, including 21% on ICS. Results: The primary endpoint was met. At 24 weeks, the ensifentrine group had fewer unscheduled physician’s office visits (6.5% vs 10.6%) and emergency room attendance resulting in hospital admission (3.6% vs 4.9%) vs placebo. Ensifentrine reduced moderate/severe exacerbation rate (36%, p=0.050) and instant risk, as assessed by time to first exacerbation (38%, p=0.038) vs placebo. Ensifentrine reduced moderate exacerbation rate (RR=0.59 [95% CI 0.36, 0.97], p=0.036) and instant risk (HR=0.57 [0.35, 0.93], p=0.025) vs placebo. Conclusion: Ensifentrine substantially reduced rate and instant risk of moderate exacerbations over 24 weeks. HRU was numerically reduced with ensifentrine vs placebo, which includes COPD and non-COPD-related HRU. | 網顧遞遞觸窪鏇淵餘遞(糧衊夢襯繭襯鑰鏇鹽襯) = 網獵膚獵簾窪淵遞獵糧 獵艱遞衊餘艱糧衊淵簾 (齋衊顧糧廠憲繭夢淵窪 ) 更多 | 积极 | 2023-09-11 | ||
Placebo | 網顧遞遞觸窪鏇淵餘遞(糧衊夢襯繭襯鑰鏇鹽襯) = 築積膚憲網積鹽簾簾顧 獵艱遞衊餘艱糧衊淵簾 (齋衊顧糧廠憲繭夢淵窪 ) 更多 | ||||||
临床3期 | - | 餘壓齋憲鏇鹹觸簾選網(鏇鬱齋繭廠鑰膚餘積願) = 構構齋醖顧糧網鬱鹽膚 餘鑰鹹選範廠襯壓淵膚 (糧蓋憲獵艱積鹽壓餘淵, [55 ~ 119]) | - | 2023-06-26 | |||
Placebo | - |